Targeting lonidamine to mitochondria mitigates lung tumorigenesis and brain metastasis

Lung cancer often has a poor prognosis, with brain metastases a major reason for mortality. We modified lonidamine (LND), an antiglycolytic drug with limited efficacy, to mitochondria-targeted mito-lonidamine (Mito-LND) which is 100-fold more potent. Mito-LND, a tumor-selective inhibitor of oxidativ...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Gang, Zhang, Qi, Pan, Jing, Lee, Yongik, Ouari, Olivier, Hardy, Micael, Zielonka, Monika, Myers, Charles R., Zielonka, Jacek, Weh, Katherine, Chang, Andrew C., Chen, Guoan, Kresty, Laura, Kalyanaraman, Balaraman, You, Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6525201/
https://www.ncbi.nlm.nih.gov/pubmed/31101821
http://dx.doi.org/10.1038/s41467-019-10042-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6525201/
https://www.ncbi.nlm.nih.gov/pubmed/31101821
http://dx.doi.org/10.1038/s41467-019-10042-1

Ejemplares similares